Connective tissue disease

PCOS Challenge Announces Family Building Grant to Help People Impacted by Polycystic Ovary Syndrome and Infertility

Retrieved on: 
Thursday, September 30, 2021
Goal, Insurance, IVF, Endometrial cancer, Stroke, Connective tissue disease, Depression, Patient, Infertility, Association, PCOS Challenge, Fertility, RMA, Empowerment, Fatty liver disease, Gaps, Child, Cardiovascular disease, Woman, Hair, Awareness, Reproductive endocrinology and infertility, Polycystic ovary syndrome, Degenerative disease, Health policy, Research, Organization, PCOS, Anxiety, Education, Pharmaceutical industry, Birth control, Medicine

PCOS is a genetic, endocrine, metabolic, and reproductive disorder that affects up to 15 percent of women in the United States. PCOS is the most common hormone disorder in women and accounts for approximately 80 percent of women with anovulatory infertility. In addition to its impact on fertility, PCOS also carries higher risks for type 2 diabetes, stroke, cardiovascular disease, endometrial cancer, nonalcoholic fatty liver disease, anxiety, depression, and other serious conditions--all at a younger age.

Key Points: 
  • ATLANTA, Sept. 30, 2021 /PRNewswire/ --PCOS Challenge: The National Polycystic Ovary Syndrome Association announces its 2021 grant to help patients struggling with infertility caused by polycystic ovary syndrome (PCOS) build their families.
  • The PCOS Challenge Family Building Grant includes a free IVF cycle and is the first grant of its kind specifically for people with infertility caused by PCOS.
  • "This year, The IVF Center: Fertility Care again donates a free IVF cycle to a PCOS patient through the PCOS Challenge Family Building Grant.
  • PCOS Challenge also offers the PCOS Confidence Grant to help patients with PCOS-related hair and skin issues.

PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity

Retrieved on: 
Monday, September 27, 2021
Clinical trial, MTS, Stroke, Queensland Brain Institute, Health, Amyotrophic lateral sclerosis, FDA, IRB, Institute, Spasticity, Patient, APHP, NSR, Disability, Connective tissue disease, Station F, Heart, GLOBE, US Foods, Food and Drug Administration, Cerebral palsy, CNRS, Neurotoxin, Multiple sclerosis, ALS, Brain, ICM, Safety, INSERM, Traumatic brain injury, Sorbonne University, Lists of diseases, Pharmaceutical industry, Medical device

This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.

Key Points: 
  • This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.
  • We are pleased to have completed this clinical trial to evaluate our MyoRegulator device, commented Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker.
  • Completion of this trial is an important step in advancing this product as a novel approach to the treatment of spasticity that does not require injected neurotoxins or sedating pharmaceuticals.
  • MyoRegulator will be the worlds first non-invasive neuromodulation device for the treatment for muscle spasticity, and will enable the treatment of patients without the need for drugs or surgery.

Aptinyx to Participate in 2021 Cantor Virtual Global Healthcare Conference

Retrieved on: 
Monday, September 20, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Conference, Twitter, Brain, NMDA, APTX, Connective tissue disease, Chronic pain, Government budget balance, Inc., Nasdaq, Central nervous system, Lists of diseases, Post-traumatic stress disorder, Pharmaceutical industry

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021 at 10:00 a.m.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment.
  • For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx .

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

Retrieved on: 
Thursday, September 16, 2021
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Lists of diseases, U.S. Securities and Exchange Commission, Chronic pain, Security (finance), Achievement, Central nervous system, Trial of the century, Post-traumatic stress disorder, NMDA, Patient, Government budget balance, Connective tissue disease, Private Securities Litigation Reform Act, Nasdaq, APTX, Annual report, Inc., Solution, Growth, COVID-19, Twitter, Brain, Goal, Pharmaceutical industry, Management

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV).

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV).
  • The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.
  • We are pleased with the terms of the loan and the flexibility this facility offers to Aptinyx.
  • The K2HV team has an excellent track record of partnering with innovative growth companies and an astute perspective on R&D value creation.

Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Tuesday, August 31, 2021
Biotechnology, Pharmaceutical, Health, NMDA, Connective tissue disease, Conference, APTX, Central nervous system, Twitter, Government budget balance, Lists of diseases, Nasdaq, Brain, Post-traumatic stress disorder, Chronic pain, Inc., Pharmaceutical industry

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.
  • The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Monday, September 13, 2021.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx .

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Connective tissue disease, COO, Administration, Investor, Baxter International, CEO, R, APTX, Caregiver, NMDA, Patient, University, BA, Trial of the century, Private Securities Litigation Reform Act, Chronic pain, U.S. Securities and Exchange Commission, Partnership, DSM-5, Security (finance), Enrollment, Annual report, Lewy body, Brain, Fibromyalgia, Government budget balance, Boston Consulting Group, COVID-19, Form 10-K, Lists of diseases, Twitter, Central nervous system, Inc., Doctor of Philosophy, Dementia, Baxter, Nasdaq, Post-traumatic stress disorder, Leadership, Total, Boston, FDA, Research, BM, Type C, MD, Research and development, ID, Pharmaceutical industry, Management, Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.
  • Study 1 is expected to commence in the fourth quarter of 2021 and Study 2 is expected to commence in the first quarter of 2022.
  • Net Loss: For the second quarter of 2021, the net loss was $19.9 million compared to a net loss of $12.6 million for the second quarter of 2020.
  • ET to review its financial results and highlights for the second quarter of 2021 and subsequent period.

Global Autoimmune Disease Diagnosis Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 15, 2020
Health, Other Health, Medical specialties, Autoimmune diseases, Medicine, Clinical medicine, Autoimmunity, Immunology, Autoimmune disease, Connective tissue disease

The "Autoimmune Disease Diagnosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autoimmune Disease Diagnosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global autoimmune disease diagnosis market grew at a CAGR of around 8% during 2014-2019.
  • Looking forward, the publisher expects the global autoimmune disease diagnosis market to continue its moderate growth during the next five years.
  • An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body.

Global $6.7 Billion Autoimmune Diseases Diagnostics Market to 2025: Use of Biosensors for Autoimmune Disease Diagnosis & Adoption to Advanced Therapeutics

Retrieved on: 
Wednesday, November 4, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, Autoimmune diseases, Autoimmunity, Autoimmune disease, Immune system, Sjögren syndrome, Disease, Connective tissue disease, Evans syndrome

Disorders related to the immune system usually occur due to low activity or overactivity of the immune system.

Key Points: 
  • Disorders related to the immune system usually occur due to low activity or overactivity of the immune system.
  • An autoimmune disease is a disorder wherein one's immune system attacks the body and destroys its body tissue.
  • Factors such as a rise in the incidence of autoimmune disease have been a major driver for the growth of the market of autoimmune drugs.
  • Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.

Global Therapeutic Vaccine Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 5, 2020
Infectious diseases, Pharmaceutical, Health, Medical specialties, Medicine, Clinical medicine, RTT, Autoimmune diseases, Connective tissue diseases, Autoimmune disease, Connective tissue, Sjögren syndrome, Autoimmunity, Blood vessel, Connective tissue disease

An autoimmune disorder can lead to the growth of a tumor, damage healthy tissues, and cause changes in the function of a specific organ.

Key Points: 
  • An autoimmune disorder can lead to the growth of a tumor, damage healthy tissues, and cause changes in the function of a specific organ.
  • Autoimmune diseases can affect blood vessels, connective tissues, endocrine glands, joints, muscles, red blood cells, skin, etc.
  • Autoimmune diseases are among the top ten leading causes for death among women in all age groups, spanning to those up to 65 years.
  • Canadian and Mexican markets have high growth potentials, and the US market is focused on the invention and development of new vaccines.